Myeloid cells in tumor inflammation

Biswas SK, Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010, 11 (10): 889-896. 10.1038/ni.1937. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell. 2010, 140 (6): 883-899. 10.1016/j.cell.2010.01.025. Murray PJ, Wynn TA: Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011, 11 (11): 723-737. 10.1038/nri3073. Wynn TA, Barron L: Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis. 2010, 30 (3): 245-257. 10.1055/s-0030-1255354. Mantovani A, et al: Cancer-related inflammation. Nature. 2008, 454 (7203): 436-444. 10.1038/nature07205. Mantovani A, Sica A: Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010, 22 (2): 231-237. 10.1016/j.coi.2010.01.009. Hanahan D, Coussens LM: Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012, 21 (3): 309-322. 10.1016/j.ccr.2012.02.022. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V: Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012, 12 (4): 253-268. 10.1038/nri3175. Geissmann F, et al: Development of monocytes, macrophages, and dendritic cells. Science. 2010, 327 (5966): 656-661. 10.1126/science.1178331. Karp CL, Murray PJ: Non-canonical alternatives: what a macrophage is 4. J Exp Med. 2012, 209 (3): 427-431. 10.1084/jem.20120295. Gordon S, Martinez FO: Alternative activation of macrophages: mechanism and functions. Immunity. 2010, 32 (5): 593-604. 10.1016/j.immuni.2010.05.007. Greten FR, et al: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004, 118 (3): 285-296. 10.1016/j.cell.2004.07.013. Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005, 5 (10): 749-759. 10.1038/nri1703. Lin EY, et al: Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006, 66 (23): 11238-11246. 10.1158/0008-5472.CAN-06-1278. Qian B, et al: A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One. 2009, 4 (8): e6562-10.1371/journal.pone.0006562. Ruffell B, Affara NI, Coussens LM: Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012, 33 (3): 119-126. 10.1016/j.it.2011.12.001. Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell. 2010, 141 (1): 39-51. 10.1016/j.cell.2010.03.014. Rolny C, et al: HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011, 19 (1): 31-44. 10.1016/j.ccr.2010.11.009. Peranzoni E, et al: Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010, 22 (2): 238-244. 10.1016/j.coi.2010.01.021. Bronte V, et al: Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 2000, 96 (12): 3838-3846. Mandruzzato S, et al: IL4Ralpha + myeloid-derived suppressor cell expansion in cancer patients. J Immunol. 2009, 182 (10): 6562-6568. 10.4049/jimmunol.0803831. Corzo CA, et al: HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010, 207 (11): 2439-2453. 10.1084/jem.20100587. Corzo CA, et al: Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009, 182 (9): 5693-5701. 10.4049/jimmunol.0900092. Diaz-Montero CM, et al: Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009, 58 (1): 49-59. 10.1007/s00262-008-0523-4. Movahedi K, et al: Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008, 111 (8): 4233-4244. 10.1182/blood-2007-07-099226. Yang R, et al: CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1 + CD11b + myeloid cells. Cancer Res. 2006, 66 (13): 6807-6815. 10.1158/0008-5472.CAN-05-3755. Gallina G, et al: Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006, 116 (10): 2777-2790. 10.1172/JCI28828. Sawanobori Y, et al: Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008, 111 (12): 5457-5466. 10.1182/blood-2008-01-136895. Youn JI, et al: Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008, 181 (8): 5791-5802. Haile LA, et al: CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J Immunol. 2010, 185 (1): 203-210. 10.4049/jimmunol.0903573. Van Ginderachter JA, et al: Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood. 2006, 108 (2): 525-535. 10.1182/blood-2005-09-3777. Almand B, et al: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001, 166 (1): 678-689. Ochoa AC, et al: Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007, 13 (2 Pt 2): 721s-726s. Filipazzi P, et al: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007, 25 (18): 2546-2553. 10.1200/JCO.2006.08.5829. Hoechst B, et al: A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008, 135 (1): 234-243. 10.1053/j.gastro.2008.03.020. Vuk-Pavlovic S, et al: Immunosuppressive CD14 + HLA-DRlow/- monocytes in prostate cancer. Prostate. 2010, 70 (4): 443-455. Solito S, et al: A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. 2011, 118 (8): 2254-2265. 10.1182/blood-2010-12-325753. Luster AD, Alon R, von Andrian UH: Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 2005, 6 (12): 1182-1190. 10.1038/ni1275. Weber C, Koenen RR: Fine-tuning leukocyte responses: towards a chemokine’interactome’. Trends Immunol. 2006, 27 (6): 268-273. 10.1016/j.it.2006.04.002. Du R, et al: HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008, 13 (3): 206-220. 10.1016/j.ccr.2008.01.034. Nakasone ES, et al: Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012, 21 (4): 488-503. 10.1016/j.ccr.2012.02.017. Schmid MC, et al: Combined blockade of integrin-alpha4beta1 plus cytokines SDF-1alpha or IL-1beta potently inhibits tumor inflammation and growth. Cancer Res. 2011, 71 (22): 6965-6975. 10.1158/0008-5472.CAN-11-0588. Yang L, et al: Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1 + CD11b + myeloid cells that promote metastasis. Cancer Cell. 2008, 13 (1): 23-35. 10.1016/j.ccr.2007.12.004. Wang XQ, et al: The high level of RANTES in the ectopic milieu recruits macrophages and induces their tolerance in progression of endometriosis. J Mol Endocrinol. 2010, 45 (5): 291-299. 10.1677/JME-09-0177. Shojaei F, et al: G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A. 2009, 106 (16): 6742-6747. 10.1073/pnas.0902280106. Shojaei F, et al: Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature. 2007, 450 (7171): 825-831. 10.1038/nature06348. Denardo DG, et al: Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discov. 2011, 1: 54-67. 10.1158/2159-8274.CD-10-0028. Shimizu Y, Rose DM, Ginsberg MH: Integrins in the immune system. Adv Immunol. 1999, 72: 325-380. Shattil SJ, Kim C, Ginsberg MH: The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol. 2010, 11 (4): 288-300. 10.1038/nrm2871. Ley K, et al: Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007, 7 (9): 678-689. 10.1038/nri2156. Schmid MC, et al: Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 2011, 19 (6): 715-727. 10.1016/j.ccr.2011.04.016. Avraamides CJ, Garmy-Susini B, Varner JA: Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008, 8 (8): 604-617. 10.1038/nrc2353. Desgrosellier JS, Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010, 10 (1): 9-22. 10.1038/nrc2748. Foubert P, Varner JA: Integrins in tumor angiogenesis and lymphangiogenesis. Methods Mol Biol. 2012, 757: 471-486. Jin H, et al: Integrin alpha4beta1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Res. 2006, 66 (4): 2146-2152. 10.1158/0008-5472.CAN-05-2704. Luque A, et al: Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355–425) of the common beta 1 chain. J Biol Chem. 1996, 271 (19): 11067-11075. 10.1074/jbc.271.19.11067. Arnaout MA, Mahalingam B, Xiong JP: Integrin structure, allostery, and bidirectional signaling. Annu Rev Cell Dev Biol. 2005, 21: 381-410. 10.1146/annurev.cellbio.21.090704.151217. Ye F, et al: Recreation of the terminal events in physiological integrin activation. J Cell Biol. 2010, 188 (1): 157-173. 10.1083/jcb.200908045. Ye F, Kim C, Ginsberg MH: Reconstruction of integrin activation. Blood. 2012, 119 (1): 26-33. 10.1182/blood-2011-04-292128. Feral CC, et al: Blocking the alpha 4 integrin-paxillin interaction selectively impairs mononuclear leukocyte recruitment to an inflammatory site. J Clin Invest. 2006, 116 (3): 715-723. 10.1172/JCI26091. Manevich E, et al: Talin 1 and paxillin facilitate distinct steps in rapid VLA-4-mediated adhesion strengthening to vascular cell adhesion molecule 1. J Biol Chem. 2007, 282 (35): 25338-25348. 10.1074/jbc.M700089200. Lewis JS, et al: Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol. 2000, 192 (2): 150-158. 10.1002/1096-9896(2000)9999:9999<::AID-PATH687>3.0.CO;2-G. Sunderkotter C, et al: Macrophages and angiogenesis. J Leukoc Biol. 1994, 55 (3): 410-422. Giraudo E, Inoue M, Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004, 114 (5): 623-633. Hildenbrand R, et al: Urokinase and macrophages in tumour angiogenesis. Br J Cancer. 1995, 72 (4): 818-823. 10.1038/bjc.1995.419. Esposito I, et al: Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol. 2004, 57 (6): 630-636. 10.1136/jcp.2003.014498. Huang S, et al: Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst. 2002, 94 (15): 1134-1142. 10.1093/jnci/94.15.1134. Ostrand-Rosenberg S, Sinha P: Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009, 182 (8): 4499-4506. 10.4049/jimmunol.0802740. Munder M: Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol. 2009, 158 (3): 638-651. 10.1111/j.1476-5381.2009.00291.x. Rodriguez PC, et al: L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol. 2003, 171 (3): 1232-1239. Nagaraj S, et al: Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007, 13 (7): 828-835. 10.1038/nm1609. Sauer H, Wartenberg M, Hescheler J: Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem. 2001, 11 (4): 173-186. 10.1159/000047804. Fichtner-Feigl S, et al: Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res. 2008, 68 (9): 3467-3475. 10.1158/0008-5472.CAN-07-5301. Terabe M, et al: Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med. 2003, 198 (11): 1741-1752. 10.1084/jem.20022227. Shojaei F, et al: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b + Gr1+ myeloid cells. Nat Biotechnol. 2007, 25 (8): 911-920. 10.1038/nbt1323. Qu X, et al: Induction of Bv8 expression by granulocyte-colony stimulating factor in CD11b + Gr1+ cells: Key role of Stat3 signaling. J Biol Chem. 2012, 287 (23): 19574-19584. 10.1074/jbc.M111.326801. Shojaei F, et al: Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A. 2008, 105 (7): 2640-2645. 10.1073/pnas.0712185105. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005, 307 (5706): 58-62. 10.1126/science.1104819. Mazzieri R, et al: Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 2011, 19 (4): 512-526. 10.1016/j.ccr.2011.02.005. Stockmann C, et al: Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature. 2008, 456 (7223): 814-818. 10.1038/nature07445. Shree T, et al: Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011, 25 (23): 2465-2479. 10.1101/gad.180331.111. Squadrito ML, et al: miR-511-3p Modulates Gentic Programs of Tumor-Associated Macrophages. Cell Reports. 2012, 1: 141-154. 10.1016/j.celrep.2011.12.005. DeNardo DG, et al: CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009, 16 (2): 91-102. 10.1016/j.ccr.2009.06.018.